RxDoctor Payments Data

Shayna Castagna, PA

Physician Assistant · Phillipsburg, NJNPI 1548824170

Payments from drug & device makers

$1,182in general payments, 2019–2025

Across 73 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$765
  • Otsuka America Pharmaceutical, Inc.$125
  • Takeda Pharmaceuticals U.S.A., Inc.$101
  • Johnson & Johnson$60
  • Teva Pharmaceuticals USA, Inc.$53
  • Neurocrine Biosciences, Inc.$42
  • plus $37 from 1 others

What the payments were for

  • Food & beverage$1,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,182 in reported general payments places this provider in the 75th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$5,809
Medicare patients
20
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZyprexaOlanzapine11$27,577
RexultiBrexpiprazole11$14,992
Aripiprazole17$7,022
Lisdexamfetamine Dimesylate12$3,418
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$1,090
Vilazodone Hcl15$960
Trazodone Hcl19$297
Alprazolam32$287
Sertraline Hcl33$200
Clonazepam21$150
Fluoxetine Hcl17$143
Buspirone Hcl13$98
Lorazepam14$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$125$14,99211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Phillipsburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →